GlassScriptPhysician profile
Joseph Sireci
NPI 1659313005
$1,156.25
in general payments reported to CMS, 2019-2025
15 companies · $453 in 2025
The $453 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.27 · 2020: $12.17 · 2021: $40.38 · 2022: $54.99 · 2023: $110 · 2024: $435 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $997.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $311.14 | 2022-2025 | Evenity, Prolia, Prolia |
| Idorsia Pharmaceuticals US INC | $224.36 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $186.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $70.27 | 2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $67.12 | 2019-2021 | |
| Neos Therapeutics, LP | $65.42 | 2024 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.53 | 2025 | Caplyta |
| Indivior INC. | $48.01 | 2021-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $37.15 | 2024 | Rexulti |
| Novo Nordisk INC | $18.28 | 2024 | Rybelsus, Ozempic |
| Abbvie INC. | $17.98 | 2025 | |
| Braeburn INC. | $14.96 | 2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.26 | 2023 | Trulance |
| Evoke Pharma, INC. | $11.60 | 2021 | |
| Pfizer INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sireci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.